BPC-157 + TB-500: Tissue Repair & Recovery
A widely used injury recovery stack combining BPC-157's potent localised tissue healing with TB-500's systemic cell migration and angiogenesis support via thymosin beta-4 activity. BPC-157 focuses on tendon, ligament, and gut repair through growth factor receptor upregulation, while TB-500 accelerates broader tissue repair and reduces inflammation. The two peptides address complementary steps in the healing cascade with minimal mechanistic overlap.
Safety Notes
Both are unapproved research compounds; BPC-157 is available through some 503A compounding pharmacies for investigational use. Animal studies suggest pro-angiogenic properties — individuals with active malignancy or a history of cancer should consult a physician before use. Human clinical data for both compounds is limited, particularly for this combination. Neither is approved for use in competitive sports governed by WADA.
Peptides in This Stack
- 1BPC-157Recovery
Drives localised tissue repair by upregulating growth factor receptors (VEGF, EGF) and promoting angiogenesis at injury sites, with robust efficacy across tendon, ligament, muscle, and gut tissue in animal research.
- 2TB-500Recovery
Promotes systemic tissue repair and cell migration by upregulating actin polymerisation and reducing local inflammation, complementing BPC-157's localised signalling with broader, circulating repair activity.
Research References
Emerging
- Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157Curr Pharm Des 2013 · PMID 23127660
- Thymosin β4: a multi-functional regenerative peptideExpert Opin Biol Ther 2012 · PMID 22335423
- Novel aspects of the cytoskeletal role of thymosin-beta4FASEB J 2001 · PMID 11500374
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.